Tarsus Pharmaceuticals, Inc.

TARSSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1819790

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$17.4M	$25.8M	$25.8M	$57.0M	$0.00
Research and Development Expense	$50.3M	$42.6M	$42.6M	$41.7M	$18.8M
Selling, General and Administrative Expense	$108.7M	$44.9M	$44.9M	—	—
Operating Expenses	—	—	$88.5M	$69.2M	$27.0M
Operating Income (Loss)	-$143.2M	-$62.7M	-$62.7M	-$12.2M	-$27.0M
Interest Expense	—	—	$2.2M	$0.00	—
Nonoperating Income (Expense)	$7.3M	$617.0K	$617.0K	-$1.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$377.0M	$265.5M	$227.9M	$178.9M	$172.0M
Assets, Current	$356.7M	$256.1M	$225.4M	$176.0M	$170.7M
Cash and Cash Equivalents, at Carrying Value	$94.8M	$224.9M	$71.7M	$171.3M	$168.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$46.8M	$16.6M	$0.00	—	—
Inventory, Net	$2.6M	$3.1M	$0.00	—	—
Liabilities	$152.5M	$68.5M	$35.0M	$12.2M	$6.0M
Liabilities, Current	$80.6M	$36.9M	$15.4M	$11.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$117.5M	-$49.0M	-$49.0M	$3.7M	-$21.1M
Net Cash Provided by (Used in) Investing Activities	$140.6M	-$144.6M	-$144.6M	-$586.0K	-$456.0K
Net Cash Provided by (Used in) Financing Activities	$130.2M	$94.0M	$94.0M	$21.0K	$131.8M
Payments to Acquire Property, Plant, and Equipment	$1.5M	$506.0K	$506.0K	$586.0K	$456.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)